Discussion

UCB’s drug discovery pipeline is composed of both antibodies and small molecules. Over recent years we have successfully employed expertise from across these two fields to bring novel insights and strategies into the discovery and development of our small molecule therapeutics. My talk will review the work of these UCB experts and illustrate how lessons learnt during this period is now informing on future strategies that will hopefully deliver breakthrough therapeutics for unmet patient need.